

Dag Nyholm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2287434/publications.pdf>

Version: 2024-02-01

118
papers

4,847
citations

109321

35
h-index

102487

66
g-index

123
all docs

123
docs citations

123
times ranked

3347
citing authors

#	ARTICLE	IF	CITATIONS
1	Irreversible motor impairment in young addicts ? ephedrone, manganism or both?. Acta Neurologica Scandinavica, 2007, 115, 385-389.	2.1	1,023
2	Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology, 2005, 64, 216-223.	1.1	407
3	Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets. Clinical Neuropharmacology, 2003, 26, 156-163.	0.7	206
4	Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurologica Scandinavica, 2001, 104, 343-348.	2.1	150
5	Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease. Clinical Pharmacokinetics, 2006, 45, 109-136.	3.5	139
6	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	3.6	128
7	Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 63-73.	0.7	108
8	Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 193-203.	3.3	92
9	Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients. AAPS Journal, 2013, 15, 316-323.	4.4	83
10	Levodopa/Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. CNS Drugs, 2016, 30, 381-404.	5.9	81
11	Levodopa Pharmacokinetics and Motor Performance During Activities of Daily Living in Patients With Parkinson's Disease on Individual Drug Combinations. Clinical Neuropharmacology, 2002, 25, 89-96.	0.7	78
12	Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. European Journal of Neurology, 2012, 19, 1079-1085.	3.3	75
13	Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Review of Neurotherapeutics, 2006, 6, 1403-1411.	2.8	72
14	Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study. Movement Disorders, 2017, 32, 283-286.	3.9	70
15	A new computer method for assessing drawing impairment in Parkinson's disease. Journal of Neuroscience Methods, 2010, 190, 143-148.	2.5	68
16	Duodopa® treatment for advanced Parkinson's disease: A review of efficacy and safety. Parkinsonism and Related Disorders, 2012, 18, 916-929.	2.2	68
17	Levodopa Infusion Therapy in Parkinson Disease. Clinical Neuropharmacology, 2004, 27, 245-256.	0.7	58
18	Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease. Movement Disorders, 2004, 19, 446-451.	3.9	57

#	ARTICLE	IF	CITATIONS
19	Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements. <i>Neurology</i> , 2005, 65, 1506-1507.	1.1	56
20	Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. <i>Acta Neurologica Scandinavica</i> , 2012, 126, e29-e33.	2.1	54
21	A computer vision framework for finger-tapping evaluation in Parkinson's disease. <i>Artificial Intelligence in Medicine</i> , 2014, 60, 27-40.	6.5	53
22	Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. <i>Acta Neurologica Scandinavica</i> , 2008, 118, 379-386.	2.1	51
23	Automatic Spiral Analysis for Objective Assessment of Motor Symptoms in Parkinson's Disease. <i>Sensors</i> , 2015, 15, 23727-23744.	3.8	51
24	A home environment test battery for status assessment in patients with advanced Parkinson's disease. <i>Computer Methods and Programs in Biomedicine</i> , 2010, 98, 27-35.	4.7	49
25	The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S13-S17.	2.2	47
26	Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 237-243.	2.1	44
27	Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 17-23.	2.2	43
28	An automatic dose dispenser for microtablets—a new concept for individual dosage of drugs in tablet form. <i>International Journal of Pharmaceutics</i> , 2003, 261, 137-146.	5.2	42
29	Use of ¹¹ C-PE2I PET in Differential Diagnosis of Parkinsonian Disorders. <i>Journal of Nuclear Medicine</i> , 2015, 56, 234-242.	5.0	41
30	Motor fluctuations and <i>Helicobacter pylori</i> in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2974-2980.	3.6	40
31	Continuous Drug Delivery in Parkinson's Disease. <i>CNS Drugs</i> , 2014, 28, 19-27.	5.9	40
32	Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 563-571.	1.9	40
33	A smartphone-based system to quantify dexterity in Parkinson's disease patients. <i>Informatics in Medicine Unlocked</i> , 2017, 9, 11-17.	3.4	40
34	A Treatment-Response Index From Wearable Sensors for Quantifying Parkinson's Disease Motor States. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2018, 22, 1341-1349.	6.3	40
35	Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 345-348.	2.1	39
36	Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. <i>European Journal of Neurology</i> , 2012, 19, 820-826.	3.3	39

#	ARTICLE	IF	CITATIONS
37	Automatic and Objective Assessment of Alternating Tapping Performance in Parkinson's Disease. <i>Sensors</i> , 2013, 13, 16965-16984.	3.8	36
38	Pharmacokinetics of Levodopa/Carbidopa Microtablets Versus Levodopa/Benserazide and Levodopa/Carbidopa in Healthy Volunteers. <i>Clinical Neuropharmacology</i> , 2012, 35, 111-117.	0.7	35
39	Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. <i>European Journal of Neurology</i> , 2010, 17, 260-266.	3.3	33
40	Initial Experience of the Levodopa/Entacapone/Carbidopa Intestinal Gel in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2021, 11, 254.	2.5	33
41	New developments in levodopa therapy. <i>Neurology</i> , 2004, 62, S9-16.	1.1	33
42	A Pharmacokinetic-Pharmacodynamic Model for Duodenal Levodopa Infusion. <i>Clinical Neuropharmacology</i> , 2011, 34, 61-65.	0.7	30
43	Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects. <i>Scientific Reports</i> , 2019, 9, 4129.	3.3	30
44	Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication) in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 719-728.	2.8	29
45	Levodopa/entacapone/carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211080.	3.5	28
46	Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 6-14.	0.7	25
47	PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 606-615.	3.9	25
48	Circadian Rhythmicity in Levodopa Pharmacokinetics in Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2010, 33, 181-185.	0.7	24
49	Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. <i>Acta Neurologica Scandinavica</i> , 2013, 127, 124-132.	2.1	24
50	A web application for follow-up of results from a mobile device test battery for Parkinson's disease patients. <i>Computer Methods and Programs in Biomedicine</i> , 2011, 104, 219-226.	4.7	22
51	Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden. <i>Applied Health Economics and Health Policy</i> , 2009, 7, 167-180.	2.1	21
52	Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 171-187.	3.5	21
53	How satisfied are cervical dystonia patients after 3 years of botulinum toxin type A treatment? Results from a prospective, long-term observational study. <i>Journal of Neurology</i> , 2019, 266, 3038-3046.	3.6	21
54	Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1000-1001.	2.2	20

#	ARTICLE	IF	CITATIONS
55	A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1. <i>Clinical Neuropharmacology</i> , 2015, 38, 170-176.	0.7	20
56	Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 439-447.	3.9	20
57	Effects of <i>Helicobacter pylori</i> on Levodopa Pharmacokinetics. <i>Journal of Parkinson's Disease</i> , 2021, 11, 61-69.	2.8	20
58	Development of new levodopa treatment strategies in Parkinson's disease "from bedside to bench to bedside. <i>Upsala Journal of Medical Sciences</i> , 2017, 122, 71-77.	0.9	19
59	Evaluation of zero-echo-time attenuation correction for integrated PET/MR brain imaging "comparison to head atlas and ⁶⁸ Ge-transmission-based attenuation correction. <i>EJNMMI Physics</i> , 2018, 5, 20.	2.7	19
60	Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements. <i>Neurology</i> , 2006, 66, 1611-1612.	1.1	18
61	Imaging features associated with idiopathic normal pressure hydrocephalus have high specificity even when comparing with vascular dementia and atypical parkinsonism. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 35.	5.0	18
62	Phosphorylated α -synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. <i>Brain</i> , 2023, 146, 1065-1074.	7.6	18
63	Soft Tissue-anchored Transcutaneous Port Attached to an Intestinal Tube for Long-term Gastroduodenal Infusion of Levodopa/Carbidopa in Parkinson Disease. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 500-505.	0.5	17
64	Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. <i>Scientific Reports</i> , 2020, 10, 18057.	3.3	17
65	Clinical Experience of Dose Conversion Ratios Between 2 Botulinum Toxin Products in the Treatment of Cervical Dystonia. <i>Clinical Neuropharmacology</i> , 2012, 35, 278-282.	0.7	16
66	Verification of a Method for Measuring Parkinson's Disease Related Temporal Irregularity in Spiral Drawings. <i>Sensors</i> , 2017, 17, 2341.	3.8	16
67	An updated calculator for determining levodopa-equivalent dose. <i>Neurological Research and Practice</i> , 2021, 3, 58.	2.0	16
68	Feasibility of spirometry features for objective assessment of motor function in Parkinson's disease. <i>Artificial Intelligence in Medicine</i> , 2017, 81, 54-62.	6.5	15
69	Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience. <i>Journal of Neurology</i> , 2019, 266, 651-658.	3.6	15
70	Levodopa Fractionation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 89-96.	2.8	14
71	A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 329-332.	3.9	14
72	Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia "a phase 1b trial. <i>Npj Parkinson's Disease</i> , 2018, 4, 35.	5.3	14

#	ARTICLE	IF	CITATIONS
73	Motion Sensor-Based Assessment of Parkinson's Disease Motor Symptoms During Leg Agility Tests: Results From Levodopa Challenge. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 111-119.	6.3	14
74	Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 509-513.	2.2	13
75	Validation of a home environment test battery for supporting assessments in advanced Parkinson's disease. <i>Neurological Sciences</i> , 2012, 33, 831-838.	1.9	13
76	Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 1829-1834.	6.3	13
77	Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1299-1307.	1.9	13
78	A multiple motion sensors index for motor state quantification in Parkinson's disease. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 189, 105309.	4.7	12
79	A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. <i>Movement Disorders</i> , 2020, 35, 1046-1054.	3.9	12
80	Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 481-491.	3.9	12
81	Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 208-215.	2.1	11
82	The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 545-552.	1.7	11
83	Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. <i>Annals of Neurology</i> , 2011, 69, 424-424.	5.3	10
84	Validation of parametric methods for [11C]PE2I positron emission tomography. <i>NeuroImage</i> , 2013, 74, 172-178.	4.2	10
85	First clinical experience with levodopa/carbidopa microtablets in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 727-731.	2.1	10
86	The effect of continuous levodopa treatment during the afternoon hours. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 70-75.	2.1	10
87	Individual dose-response models for levodopa infusion dose optimization. <i>International Journal of Medical Informatics</i> , 2018, 112, 137-142.	3.3	9
88	Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus. <i>Journal of Neuroimaging</i> , 2022, 32, 90-96.	2.0	9
89	Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000200804.	1.1	9
90	Computer Vision Methods for Parkinsonian Gait Analysis: A Review on Patents. <i>Recent Patents on Biomedical Engineering</i> , 2013, 6, 97-108.	0.5	8

#	ARTICLE	IF	CITATIONS
91	Accuracy and precision of zero-echo-time, single- and multi-atlas attenuation correction for dynamic [11C]PE2I PET-MR brain imaging. <i>EJNMMI Physics</i> , 2020, 7, 77.	2.7	7
92	Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 15.	5.0	7
93	Using measurements from wearable sensors for automatic scoring of Parkinson's disease motor states: Results from 7 patients. , 2017, 2017, 131-134.		6
94	Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1529-1534.	2.8	6
95	Personalized Medicine Approach in Treating Parkinson's Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2021, 11, 720.	2.5	6
96	Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 78-84.	2.1	5
97	Close relationships in Parkinson's disease patients with device-aided therapy. <i>Brain and Behavior</i> , 2021, 11, e02102.	2.2	5
98	Development of a clinically feasible [C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 263-274.	1.0	5
99	Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 686-687.	2.2	4
100	Spiral drawing during self-rated dyskinesia is more impaired than during self-rated off. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 553-556.	2.2	4
101	Stochastic anomaly detection in eye-tracking data for quantification of motor symptoms in Parkinson's disease. <i>AIP Conference Proceedings</i> , 2013, , .	0.4	4
102	Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa/carbidopa intestinal gel in the absence of head-to-head comparisons. <i>Basal Ganglia</i> , 2012, 2, 221-226.	0.3	3
103	Visualization of Spiral Drawing Data of Patients with Parkinson's Disease. , 2014, , .		3
104	Composite attenuation correction method using a 68Ge-transmission multi-atlas for quantitative brain PET/MR. <i>Physica Medica</i> , 2022, 97, 36-43.	0.7	3
105	Evaluation of a sensor algorithm for motor state rating in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 112-117.	2.2	2
106	Long-term Efficacy and Safety with Continuous Dopaminergic Stimulation Pump Treatments in Parkinson's Disease. <i>European Neurological Review</i> , 2011, 6, 156.	0.5	2
107	Pain, disease severity and associations with individual quality of life in patients with motor neuron diseases. <i>BMC Palliative Care</i> , 2021, 20, 154.	1.8	2
108	Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System. <i>JMIR Formative Research</i> , 2022, 6, e31485.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Authors'™ Reply to Lambarth: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's™ Disease: A Systematic Review". CNS Drugs, 2016, 30, 1009-1010.	5.9	1
110	A survey of lifestyle factors in dystonia. Brain and Behavior, 2020, 10, e01871.	2.2	1
111	Novel administration routes for levodopa and dopamine agonists. European Journal of Pharmaceutical Sciences, 2008, 34, S13-S14.	4.0	0
112	P1.175 Defining a test score for status assessment during motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S74.	2.2	0
113	Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e95.	2.2	0
114	Everyday Occupations and Other Factors in Relation to Mental Well-Being among Persons with Advanced Parkinson's™ Disease. Occupational Therapy in Health Care, 2020, 34, 1-18.	0.3	0
115	Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations. Recent Patents on Biomedical Engineering, 2013, 6, 127-135.	0.5	0
116	Feasibility of Spirography Features for Objective Assessment of Motor Symptoms in Parkinson's™ Disease. Lecture Notes in Computer Science, 2015, , 267-276.	1.3	0
117	Unsupervised Learning from Motion Sensor Data to Assess the Condition of Patients with Parkinson's™ Disease. Lecture Notes in Computer Science, 2019, , 420-424.	1.3	0
118	Optimizing Treatment of Parkinson's™ Disease. Journal of Personalized Medicine, 2022, 12, 245.	2.5	0